Multifunctional Mesoporous Silica Nanoparticles for Oral Drug Delivery
Source abstract
Abstract
Nanotechnology has transformed engineering designs across a wide spectrum of materials and applications. Mesoporous Silica Nanoparticles (MSNs) are one of the new fabrications of nanostructures as medication delivery systems. MSNs have pore sizes varying from 2 to 50 nm, making them ideal for a variety of biological applications. They offer unique characteristics such as a tunable surface area, well-defined surface properties, and the ability to improve drug pharmacokinetic characteristics. Moreover, they have the potential to reduce adverse effects by delivering a precise dose of medications to a specific spot rather than the more frequent systemic delivery, which diffuses across tissues and organs. In addition, the vast number of pores allow drug incorporation and transportation of drugs to various sites making MSNs a feasible platform for orally administered drugs. Though the oral route is the most suitable and convenient platform for drug delivery, conventional oral drug delivery systems are associated with several limitations. Surpassing gastrointestinal barriers and the low oral bioavailability of poorly soluble medicines pose a major challenge in the pharmaceutical industry. This review provides insights into the role of MSNs and its mechanism as an oral drug delivery system.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Advanced Drug Delivery Systems · Nanoparticle-Based Drug Delivery · Mesoporous Materials and Catalysis
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Hofuf 31982, Saudi Arabia
Department of Pharmaceutics, Vidya Siri College of Pharmacy, Bangalore 560035, India
Department of Pharmaceutics, Amrita School of Pharmacy, AIMS Health Science Campus, Amrita Vishwa Vidyapeetham, Kochi 682041, India
Department of Pharmaceutical Science, Assam University (A Central University), Silchar 788011, India
Department of Basic Medical Sciences, College of Medicine, King Faisal University, Al-Ahsa 31982, Saudi Arabia
Department of Pharmacy Practice, College of Clinical Pharmacy, King Faisal University, Al-Ahsa 31982, Saudi Arabia
School of Pharmacy, Management and Science University, Shah Alam 40100, Malaysia
Department of Pharmacy Practice, College of Pharmacy, Al Maarefa University, Dariyah, Riyadh 13713, Saudi Arabia
Department of Biotechnology and Food Science, Faculty of Applied Sciences, Durban University of Technology, Durban 4000, South Africa
Funding
King Faisal University
References (90)
Show source-provided references
1. Preparation and characterization of rifampin loaded mesoporous silica nanoparticles as a potential system for pulmonary drug delivery
2. Advances in oral drug delivery
3. Homayun, B., Lin, X., and Choi, H.-J. (2019). Challenges and recent progress in oral drug delivery systems for biopharmaceuticals. Pharmaceutics, 11.10.3390/pharmaceutics11030129 ↗
4. Smart mesoporous silica nanoparticles for controlled-release drug delivery10.1515/ntrev-2015-0057 ↗
5. Ufasomes: Unsaturated fatty acid based vesicular drug delivery system10.22159/ijap.2021v13i2.39526 ↗
6. Mesoporous silica nanoparticles for therapeutic/diagnostic applications10.1016/j.biopha.2018.10.167 ↗
7. Mesoporous silica nanoparticles in target drug delivery system: A review10.4103/2230-973X.160844 ↗
8. Mesoporous silica nanoparticles for drug and gene delivery10.1016/j.apsb.2018.01.007 ↗
9. Pal, N., Lee, J.H., and Cho, E.B. (2020). Recent trends in morphology-controlled synthesis and application of mesoporous silica nanoparticles. Nanomaterials, 10.10.3390/nano10112122 ↗
10. Synthesis and characterization of positive-charge functionalized mesoporous silica nanoparticles for oral drug delivery of an anti-inflammatory drug10.1002/adfm.200800521 ↗
11. Mitran, R.-A., Deaconu, M., Matei, C., and Berger, D. (2019). Mesoporous silica as carrier for drug-delivery systems. Nanocarriers for Drug Delivery, Elsevier.10.1016/B978-0-12-814033-8.00011-4 ↗
12. Mesoporous silica nanoparticles for bio-applications10.3389/fmats.2020.00036 ↗
13. Pednekar, P.P., Godiyal, S.C., Jadhav, K.R., and Kadam, V.J. (2017). Mesoporous silica nanoparticles: A promising multifunctional drug delivery system. Nanostructures for Cancer Therapy, Elsevier.10.1016/B978-0-323-46144-3.00023-4 ↗
14. Evaluation of mesoporous silica nanoparticles for oral drug delivery–current status and perspective of MSNs drug carriers10.1039/C7NR05762H ↗
15. Mesoporous Silica Nanoparticles: Synthesis, Modification and Applications
16. Narayan, R., Nayak, U.Y., Raichur, A.M., and Garg, S. (2018). Mesoporous silica nanoparticles: A comprehensive review on synthesis and recent advances. Pharmaceutics, 10.10.3390/pharmaceutics10030118 ↗
17. Sol gel-derived SBA-16 mesoporous material10.3390/ijms11093069 ↗
18. Martins, A., Nunes, N., Carvalho, A.P., and Martins, L.M.D.R.S. (2022). Zeolites and related materials as catalyst supports for hydrocarbon oxidation reactions. Catalysts, 12.10.3390/catal12020154 ↗
19. Mesoporous silica based gold catalysts: Novel synthesis and application in catalytic oxidation of CO and volatile organic compounds (VOCs)10.3390/catal3040774 ↗
20. Amin, M.H. (2020). Relationship between the pore structure of mesoporous silica supports and the activity of nickel nanocatalysts in the CO2 reforming of methane. Catalysts, 10.10.3390/catal10010051 ↗
21. Vallet-Regí, M. (2012). Mesoporous silica nanoparticles: Their projection in nanomedicine. Int. Sch. Res. Not., 2012.10.5402/2012/608548 ↗
22. Mesoporous silica nanoparticles: A review10.4172/2329-6631.1000174 ↗
23. Mesoporous silica nanorods for improved oral drug absorption10.1080/21691401.2017.1362414 ↗
24. Gisbert-Garzarán, M., Manzano, M., and Vallet-Regí, M. (2020). Mesoporous silica nanoparticles for the treatment of complex bone diseases: Bone cancer, bone infection and osteoporosis. Pharmaceutics, 12.10.3390/pharmaceutics12010083 ↗
25. Multilayer encapsulated mesoporous silica nanospheres as an oral sustained drug delivery system for the poorly water-soluble drug felodipine10.1016/j.msec.2014.10.067 ↗
26. Formulation of tablets containing mesoporous silica nanoparticles loaded with pramipexole
27. Bioavailability and dissolution rate enhancement of an anticancer drug bicalutamide by encapsulation into mesoporous silica nanoparticles: Effects of amine functionalization and Caco-2 cell permeability study10.5530/ijper.54.3.108 ↗
28. Surface decorated mesoporous silica nanoparticles: A promising and emerging tool for cancer targeting10.5530/ijper.53.3.72 ↗
29. Rotation-facilitated rapid transport of nanorods in mucosal tissues10.1021/acs.nanolett.6b03515 ↗
30. Role of nanoparticle size, shape and surface chemistry in oral drug delivery10.1016/j.jconrel.2016.07.051 ↗
31. Hydrogels as drug delivery systems; pros and cons
32. Polymeric micelles for oral drug administration enabling locoregional and systemic treatments10.1517/17425247.2015.960841 ↗
33. Highlights in mesoporous silica nanoparticles as a multifunctional controlled drug delivery nanoplatform for infectious diseases treatment10.1007/s11095-020-02917-6 ↗
34. Influences of material characteristics on ibuprofen drug loading and release profiles from ordered micro-and mesoporous silica matrices10.1021/cm0401490 ↗
35. Oral administration of salecan-based hydrogels for controlled insulin delivery10.1021/acs.jafc.8b02879 ↗
36. Salecan-based pH-sensitive hydrogels for insulin delivery10.1021/acs.molpharmaceut.6b00875 ↗
37. Zhu, L., Lu, L., Wang, S., Wu, J., Shi, J., Yan, T., Xie, C., Li, Q., Hu, M., and Liu, Z. (2017). Oral absorption basics: Pathways and physicochemical and biological factors affecting absorption. Developing Solid Oral Dosage Forms, Elsevier.10.1016/B978-0-12-802447-8.00011-X ↗
38. Lipophilic peptide character—What oral barriers fear the most10.1016/j.jconrel.2017.04.038 ↗
39. Calcagno, A.M., and Siahaan, T.J. (2005). Physiological, biochemical, and chemical barriers to oral drug delivery. Drug Delivery: Principles and Applications, John Wiley & Sons.10.1002/0471475734.ch2 ↗
40. Lipid-coated MCM-41 mesoporous silica nanoparticles loaded with berberine improved inhibition of acetylcholine esterase and amyloid formation10.1021/acsbiomaterials.1c00514 ↗
41. Lipid coated mesoporous silica nanoparticles as an oral delivery system for targeting and treatment of intravacuolar Salmonella infections10.1039/C4RA12973C ↗
42. Bansal, K.K., Mishra, D.K., Rosling, A., and Rosenholm, J.M. (2020). Therapeutic potential of polymer-coated mesoporous silica nanoparticles. Appl. Sci., 10.10.3390/app10010289 ↗
43. Silver-incorporated mussel-inspired polydopamine coatings on mesoporous silica as an efficient nanocatalyst and antimicrobial agent10.1021/acsami.7b18136 ↗
44. Synthesis and modification of crystalline SBA-15 nanowhiskers as a pH-sensitive metronidazole nanocarrier system10.1016/j.ijpharm.2018.11.034 ↗
45. Mesoporous silica nanoparticles for increasing the oral bioavailability and permeation of poorly water soluble drugs10.1021/mp200287c ↗
46. Gastro-protective protein-silica nanoparticles formulation for oral drug delivery: In vitro release, cytotoxicity and mitochondrial activity10.1016/j.ejpb.2020.03.015 ↗
47. Mesoporous silica nanoparticles: Synthesis, pharmaceutical applications, biodistribution, and biosafety assessment10.1016/j.cej.2018.11.156 ↗
48. The preparation of alkyltrimethylammonium–kanemite complexes and their conversion to microporous materials10.1246/bcsj.63.988 ↗
49. A new family of mesoporous molecular sieves prepared with liquid crystal templates10.1021/ja00053a020 ↗
50. Downing, M.A., and Jain, P.K. (2020). Mesoporous silica nanoparticles: Synthesis, properties, and biomedical applications. Nanoparticles for Biomedical Applications, Elsevier.10.1016/B978-0-12-816662-8.00016-3 ↗
51. Mesoporous silica and organosilica nanoparticles: Physical chemistry, biosafety, delivery strategies, and biomedical applications10.1002/adhm.201700831 ↗
52. Mesoporous silica nanoparticles as nanocarriers10.1039/c1cc11760b ↗
53. Tunable synthesis of mesoporous silica particles with unique radially oriented pore structures from tetramethyl orthosilicate via oil–water emulsion process10.1021/acs.langmuir.6b04023 ↗
54. Syntheses and applications of periodic mesoporous organosilica nanoparticles10.1039/C5NR05649G ↗
55. Synthesis of mesoporous silica nanoparticles10.1039/c3cs35405a ↗
56. Synthesis and drug delivery applications for mesoporous silica nanoparticles
57. Effect of surface properties on nanoparticle-cell interactions10.1002/smll.200901158 ↗
58. Mesoporous silica nanoparticles for reducing hemolytic activity towards mammalian red blood cells10.1002/smll.200800926 ↗
59. Role of mesoporous silica nanoparticles for the drug delivery applications10.1088/2053-1591/abbf7e ↗
60. Martínez-Edo, G., Balmori, A., Pontón, I., Martí del Rio, A., and Sánchez-García, D. (2018). Functionalized ordered mesoporous silicas (MCM-41): Synthesis and applications in catalysis. Catalysts, 8.10.3390/catal8120617 ↗
61. Sun, X. (2012). Mesoporous Silica Nanoparticles for Applications in Drug Delivery and Catalysis. [Ph.D. Thesis, Iowa State University].
62. Effect of methanol concentration on CTAB micellization and on the formation of surfactant-templated silica (STS)10.1021/cm970240m ↗
63. Hybrid inorganic-organic mesoporous silicates-nanoscopic reactors coming of age10.1002/1521-4095(200010)12:19<1403::AID-ADMA1403>3.0.CO;2-X ↗
64. Template removal and thermal stability of organically functionalized mesoporous silica nanoparticles10.1021/cm060598v ↗
65. A polyamidoamine dendrimer-capped mesoporous silica nanosphere-based gene transfection reagent10.1021/ja046275m ↗
66. Tri-functionalization of mesoporous silica nanoparticles for comprehensive cancer theranostics—The trio of imaging, targeting and therapy10.1039/c0jm00645a ↗
67. Enhancing oral bioavailability of poorly soluble drugs with mesoporous silica based systems: Opportunities and challenges10.1080/03639045.2018.1542709 ↗
68. Incorporation of clotrimazole in ordered mesoporous silica by supercritical CO210.1016/j.micromeso.2014.05.031 ↗
69. Mesoporous silica nanoparticles as potential carriers for enhanced drug solubility of paclitaxel10.1016/j.msec.2017.04.049 ↗
70. Synthesis and surface modification of mesoporous silica nanoparticles and its application as carriers for sustained drug delivery10.3109/10717544.2013.838715 ↗
71. Increasing the oral bioavailability of poorly water-soluble carbamazepine using immediate-release pellets supported on SBA-15 mesoporous silica
72. The absorption, distribution, excretion and toxicity of mesoporous silica nanoparticles in mice following different exposure routes10.1016/j.biomaterials.2012.12.043 ↗
73. Mesoporous silica nanoparticles: Synthesis, classification, drug loading, pharmacokinetics, biocompatibility, and application in drug delivery10.1080/17425247.2019.1575806 ↗
74. Tissue distribution and excretion kinetics of orally administered silica nanoparticles in rats
75. Ordered mesoporous materials for drug delivery10.1016/j.micromeso.2008.07.002 ↗
76. Influence of pore size of MCM-41 matrices on drug delivery rate10.1016/j.micromeso.2003.12.012 ↗
77. Mesoporous silica nanoparticles in medicine—Recent advances10.1016/j.addr.2012.07.018 ↗
78. Mesoporous silica nanoparticles for protein protection and delivery10.3389/fchem.2019.00290 ↗
79. Carroll, M., Woodward, R., House, M., Pierre, T.S., Huffstetler, P., Miles, W., Davis, R., and Riffle, J. (2011). Diagnosing Diseases with Rust: MagnetiC nanopaRtiCles foR BioMeDiCal iMaging. Nanotechnology in Australia: Showcase of Early Career Research, CRC Press.
80. Mesoporous silica nanoparticles in drug delivery and biomedical applications10.1016/j.nano.2014.09.014 ↗
81. An overview on the role of silica-based materials in vaccine development10.1080/14760584.2016.1188009 ↗
82. Toxicity of cationic lipids and cationic polymers in gene delivery10.1016/j.jconrel.2006.04.014 ↗
83. Mucoadhesive vs. mucopenetrating particulate drug delivery10.1016/j.ejpb.2015.11.003 ↗
84. Carrier based oral nano drug delivery framework: A review10.2174/2405461503666180703094241 ↗
85. Nanotechnology: A boon in oral cancer diagnosis and therapeutics10.4103/0976-433X.125591 ↗
86. Trucillo, P. (2021). Drug carriers: Classification, administration, release profiles, and industrial approach. Processes, 9.10.3390/pr9030470 ↗
87. Potential enhancement and targeting strategies of polymeric and lipid-based nanocarriers in dermal drug delivery10.4155/tde-2017-0075 ↗
88. Advantages and risks of nanotechnologies in cancer patients and occupationally exposed workers10.1517/17425247.2014.913568 ↗
89. A review on current nanomaterials and their drug conjugate for targeted breast cancer treatment10.2147/IJN.S127329 ↗
90. Silica-based systems for oral delivery of drugs, macromolecules and cells10.1016/j.cis.2017.04.005 ↗